These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 31117130)
1. Erratum to Giangrande et al. "Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A" (Thromb Haemost 2017; 117: 252-261). Thromb Haemost; 2017 Jun; 117(6):1163. PubMed ID: 31117130 [No Abstract] [Full Text] [Related]
2. Erratum to Fischer et al. "Inhibitor development in nonsevere haemophilia across Europe" (Thromb Haemost 2015; 114: 670-675). Thromb Haemost; 2016 Mar; 115(3):684. PubMed ID: 26922949 [TBL] [Abstract][Full Text] [Related]
3. Erratum to Kooistra et al. "Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients" (Thromb Haemost 2015; 113: 881-890). Thromb Haemost; 2015 Aug; 114(3):656. PubMed ID: 26320573 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J; Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108 [TBL] [Abstract][Full Text] [Related]
7. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862 [TBL] [Abstract][Full Text] [Related]
8. Erratum to Parasrampuria et al. "Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis" (Thromb Haemost 2015; 113: 719-727). Thromb Haemost; 2017 Apr; 117(4):821. PubMed ID: 28367580 [TBL] [Abstract][Full Text] [Related]
9. Erratum to Loboda et al. "Carbon monoxide: pro- or anti-angiogenic agent? Comment on Ahmad et al. (Thromb Haemost 2015; 113: 329-337). Thromb Haemost; 2016; 116(1):203. PubMed ID: 27374429 [TBL] [Abstract][Full Text] [Related]
10. Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400). Thromb Haemost; 2017 Feb; 117(3):643. PubMed ID: 28245032 [No Abstract] [Full Text] [Related]
11. Erratum to Sala et al. "MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice" (Thromb Haemost 2014; 112: 796-802). Thromb Haemost; 2015 Jul; 114(1):210. PubMed ID: 26125660 [No Abstract] [Full Text] [Related]
12. Erratum to Rutten et al. "Platelet density per monocyte predicts adverse events in patients after percutaneous coronary intervention" (Thromb Haemost 2016; 115: 353-360). Thromb Haemost; 2017 Feb; 117(3):641. PubMed ID: 28245033 [No Abstract] [Full Text] [Related]
13. Erratum to Hillis et al. "Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants" (Thromb Haemost 2014; 113: 1193-1201). Thromb Haemost; 2015 Jul; 114(1):210. PubMed ID: 26125661 [No Abstract] [Full Text] [Related]
14. Erratum to Pottegård et al. "Antithrombotic drugs and subarachnoid haemorrhage risk: A nationwide case-control study in Denmark" (Thromb Haemost 2014; 5: 1064-1075). Thromb Haemost; 2016 May; 115(5):1079. PubMed ID: 27137945 [TBL] [Abstract][Full Text] [Related]
15. Erratum to Palareti et al. "The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study" (Thromb Haemost 2016; 115: 1101-1108). Thromb Haemost; 2016 Aug; 116(2):396. PubMed ID: 27476951 [TBL] [Abstract][Full Text] [Related]
16. Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197). Thromb Haemost; 2016 Sep; 116(4):775. PubMed ID: 27670439 [TBL] [Abstract][Full Text] [Related]
17. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071 [TBL] [Abstract][Full Text] [Related]
18. Erratum to "Adipokines at the crossroad between obesity and cardiovascular disease" (Thromb Haemost 2015; 113: 553-566). Molica F; Morel S; Kwak BR; Rohner-Jeanrenaud F; Steffens S Thromb Haemost; 2015 Apr; 113(4):909. PubMed ID: 25822650 [No Abstract] [Full Text] [Related]
19. Rebuttal to Partsch et al. "Pain relief by compression in acute DVT. A critique of Kahn et al." Thromb Haemost 2015; 113: 906. Kahn SR; Shapiro S; Ginsberg JS Thromb Haemost; 2015 Apr; 113(4):907. PubMed ID: 25739814 [No Abstract] [Full Text] [Related]
20. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]